Five Under 5: Top Oncology Videos for the Week of 8/10

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Induction Chemoimmunotherapy Followed by High-Dose Chemo and ASCT in Younger Patients With MCL: Mats Jerkeman, MD

Mats Jerkeman, MD, of Lund University in Sweden, discussed long-term outcomes from the phase 2 Nordic MCL2 (ISRCTN87866680) and MCL3 (NCT00514475) trials in younger patients with mantle cell lymphoma (MCL). He noted that at a median follow-up of 18 years, excess mortality persisted in the overall cohort, although patients aged 50 years or younger at diagnosis showed no excess mortality compared with the general population. Approximately 25% of trial participants remained alive and in their first complete remission after 20 years, suggesting potential for functional or clinical cure in select patients. Jerkeman emphasized that the data highlight both the curative potential of intensive frontline therapy and the need for continued surveillance to address late relapses and long-term toxicities.

Niraparib Plus Abiraterone Acetate and Prednisone in HRR+ mCSPC: Dana E. Rathkopf, MD

Dana E. Rathkopf, MD, of Memorial Sloan Kettering Cancer Center, discussed data from the phase 3 AMPLITUDE trial (NCT04497844) evaluating niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone in patients with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC). She noted that patients receiving the combination achieved a median radiographic progression-free survival (PFS) that was not evaluable vs 29.5 months with placebo plus abiraterone and prednisone (HR, 0.63; P = .0001), meeting the trial’s primary end point. Rathkopf added that the regimen also significantly improved time to symptomatic progression (HR, 0.50; P < .0001) and was generally well tolerated, despite grade 3/4 adverse effects (AEs) in 75% of patients. She emphasized that this targeted approach is particularly important for those with HRR-mutated mCSPC, who typically have a worse prognosis, as it offers an opportunity to maximize clinical outcomes.

Ongoing Research Priorities for NF1-Associated Plexiform Neurofibromas: Timothy Gershon, MD, PhD

Timothy R. Gershon, MD, PhD, of Emory University School of Medicine, discussed ongoing research priorities in the management of neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PNs). He noted that treatment options expanded after the February 2025 FDA approval of mirdametinib (Gomekli) for patients 2 years of age and older with symptomatic PNs not amenable to complete resection. Gershon emphasized that substantial unmet needs remain, particularly regarding neuropsychosocial aspects such as learning differences and autism spectrum disorder, and highlighted the lack of methods linking NF1 genotypes to neuropsychosocial phenotypes. He also discussed the continuing role of surgery, the potential for perioperative MEK inhibition, and the need for combination strategies to enhance and standardize tumor shrinkage with mirdametinib.

Role of Elacestrant in ER+/HER2– Advanced Breast Cancer: Katherine C. Ansley, MD

Katherine C. Ansley, MD, of Wake Forest University School of Medicine, discussed the role of the oral selective estrogen receptor degrader elacestrant (Oserdu) for patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer previously treated with 1 or 2 lines of therapy. She highlighted the January 2023 FDA approval of elacestrant for those with ESR1-mutated disease after prior endocrine therapy and noted significant responses in patients with liver, lung, or bone metastases in subgroup analyses of the phase 3 EMERALD trial (NCT03778931). Ansley emphasized that elacestrant is well tolerated, with mostly grade 1/2 AEs and few treatment discontinuations. She added that the therapy demonstrates improved median PFS vs standard of care, particularly in those with liver, lung, or bone metastases.

FDA Approval of Tafasitamab in R/R Follicular Lymphoma: Ajay K. Gopal, MD, FACP

Ajay K. Gopal, MD, FACP, of Fred Hutch Cancer Center and the University of Washington School of Medicine, discussed the FDA approval of tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) and rituximab (Rituxan) for patients with relapsed/refractory follicular lymphoma. The June 2025 approval, which was based on findings from the phase 3 inMIND trial (NCT04680052), provides a non-chemotherapy option in the second-line setting, where such therapies were previously limited to third line or beyond. Gopal noted that this regimen can improve PFS while reducing exposure to chemotherapy and its long-term AEs. He added that tafasitamab addresses a key unmet need in managing follicular lymphoma as a chronic disease.